Agilus Diagnostics installs Illumina NovaSeq X to revolutionise genomic testing in India

Agilus Diagnostics, a subsidiary of Fortis Healthcare, has announced the installation of the Illumina NovaSeq X at its Mumbai reference laboratory—strengthening India’s capacity for next‑generation sequencing at scale.

The launch was attended by Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare; Dr Anand K., Managing Director & CEO, Agilus Diagnostics, and Deepak Narang, Chief Operating Officer, Agilus Diagnostics.

The NovaSeq X strengthens Agilus Diagnostics’ molecular testing capabilities through high‑throughput sequencing and scalable analytics. Its multi‑omic capacity delivers rapid, high‑resolution results across diverse clinical needs. Through Agilus’ nationwide network, these advanced capabilities become accessible to clinicians and patients in both metro and emerging markets.

Powered by high‑density flow cells and automation, the NovaSeq X enables whole exome sequencing (WES), whole genome sequencing (WGS), and multi‑omic analysis with exceptional speed and accuracy. Deployed for high‑fidelity clinical decision‑making—not just research—it provides physicians with actionable molecular insights and faster turnaround times.

Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said, “Integrating advanced platforms like the Illumina NovaSeq X into clinical diagnostics is a pivotal step for India’s healthcare ecosystem. High‑quality molecular insights are vital not only for oncology but also for diagnosing rare diseases, guiding targeted therapies, and advancing personalized and preventive care. Agilus’ investment brings cutting‑edge science closer to patients and equips clinicians with actionable information to improve outcomes across a broad spectrum of conditions.”

For clinicians and researchers, the enhanced capacity translates into:

• Whole exome and whole genome testing for comprehensive variant detection
• Genetic evaluation of inherited and rare disorders
• Reproductive and maternal health applications, including carrier screening and prenatal testing
• Pharmacogenomic assessments to inform drug response and dosing
• Infectious disease sequencing for pathogen tracking and antimicrobial resistance insights
• Liquid biopsy (ctDNA) analysis and multi‑omic studies for longitudinal disease monitoring and deeper biological understanding